Investigation of non-completion factors for durvalumab maintenance therapy in locally advanced non-small cell lung cancer.

ABSTRACT:

Background

The phase III PACIFIC trial demonstrated that one year of durvalumab maintenance therapy after concurrent chemoradiotherapy (CCRT) significantly improved overall survival (OS) in unresectable stage III non-small cell lung cancer (NSCLC), reducing the risk of death by 32% compared with observation. Durvalumab therapy administered for up to 12 months is currently the standard of care for patients with locally advanced NSCLC. This study aimed to identify the factors influencing the completion of durvalumab therapy.

Methods

This retrospective study analyzed patients who initiated durvalumab therapy for unresectable NSCLC at Niigata University Medical and Dental Hospital between August 2018 and December 2022. Patients who discontinued the treatment for reasons unrelate

SUBMITTER: Kotake M 

PROVIDER: S-EPMC12605329 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature